2022
DOI: 10.1016/j.cell.2022.01.012
|View full text |Cite
|
Sign up to set email alerts
|

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

11
175
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3
1

Relationship

2
6

Authors

Journals

citations
Cited by 225 publications
(200 citation statements)
references
References 166 publications
11
175
0
Order By: Relevance
“…While single-cell sequencing technologies are capable of measuring RNA transcripts and surface proteins in thousands of single cells, cytometry-based techniques can measure both extracellular and intracellular proteins in millions of cells. As our bridge integration procedure should enable the mapping of CyTOF profiles onto scRNA-seq datasets, we obtained a collection of CyTOF datasets spanning 119 individuals and 5,170,249 total cells 62 . We used our previously collected CITE-seq dataset of 161,764 PBMC from healthy donors as a multi-omic bridge 4 .…”
Section: Resultsmentioning
confidence: 99%
“…While single-cell sequencing technologies are capable of measuring RNA transcripts and surface proteins in thousands of single cells, cytometry-based techniques can measure both extracellular and intracellular proteins in millions of cells. As our bridge integration procedure should enable the mapping of CyTOF profiles onto scRNA-seq datasets, we obtained a collection of CyTOF datasets spanning 119 individuals and 5,170,249 total cells 62 . We used our previously collected CITE-seq dataset of 161,764 PBMC from healthy donors as a multi-omic bridge 4 .…”
Section: Resultsmentioning
confidence: 99%
“…Finally, we applied SepstratifieR to two COVID-19 cohorts: the COVID-19 Multi-Omic Blood Atlas (COMBAT) 26 and the Deutsche COVID-19 Omics Initiative (DeCOI; Supplementary Table 1 ). 27 In both instances, whole-transcriptome analysis showed a clear separation between patients and controls ( Figure 6A and Supplementary Figure 6A ).…”
Section: Resultsmentioning
confidence: 99%
“…To test the validity of our results, we first sought further evidence of increased immature neutrophils in SRS1. We re-analysed whole blood bulk RNA-seq and mass cytometric (CyTOF) immunophenotyping data from a cohort of 36 all cause sepsis patients (42 samples), who were previously recruited to the same study and included as part of a bioresource from the COMBAT consortium to compare with COVID-19 patient samples (cohort 2)(26) (Fig. 1A, Table S11).…”
Section: Resultsmentioning
confidence: 99%
“…Healthy volunteers and sepsis patients were recruited into the same studies as in cohort 1 under the same criteria and ethics and were analysed previously as part of a COVID-19 centric bioresource (26).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation